UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
· FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by moderate to severe hidradenitis suppurativa (HS) · HS is a chronic, progressive, inflammatory, and scarring skin disease leading to a diminished quality of life, for which very limited treatment options exist · Orismilast is a high-potency PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of psoriasis and atopic dermatitis (AD), for which a Fast Track designation has also been